Company News

Early test results for U.S. drug ‘biggest breakthrough’ for pancreatic cancer, says Canadian oncologist

Published: 

Dr. Sam Godfrey with Cancer Research UK discusses how a pancreatic cancer pill currently in trials works and what it can do.

An experimental U.S. drug that saw positive results in patients during early tests is a major “breakthrough” for cancer patients, Canadian doctors say.

A U.S. drugmaker reported Friday that its pill, ERAS-0015, reduced tumours in nearly half of the patients with advanced pancreatic and lung cancers in an early-stage clinical trial.

Erasca, based in San Diego, Calif., said 44 per cent of 25 patients with pancreatic cancer saw tumours shrink substantially after they took a 32 mg daily dose of the drug.

Additionally, 69 per cent of patients with the two most common genetic variations of pancreatic cancer experienced positive results after taking the drug.

For lung cancer, tumours diminished in three of five patients (60 per cent) who had previously received immunotherapy and chemotherapy.

Erasca said it would begin late-stage clinical trials to test the drug and another experimental treatment called ERAS-4001 in 2027.

Dr. Jennifer Knox, staff medical oncologist at the University Health Network’s Princess Margaret Cancer Centre in Toronto, will be supervising patients when the clinical trial of the new drug comes to Canada next year as part of the global tests.

“It’s the biggest breakthrough for pancreas cancer probably ever,” Knox said in a phone interview with CTVNews.ca on Friday. “It’s one of the biggest breakthroughs for cancer in general in recent years.”

However, the early stage of the Erasca trial only involved a small number of patients, which Knox said is “typical” at that phase. She expects a large number of people to participate in the upcoming clinical trial in Canada, she added.

A doctor tends to patients in his office in Illinois on Oct. 30, 2012. (Jeff Roberson / AP)
Pancreatic cancer doctor A doctor tends to patients in his office in Illinois on Oct. 30, 2012. (Jeff Roberson / AP)

‘Big breakthrough’ with another drug

Knox said the first “big breakthrough” targeting the mutant RAS protein that’s present in around 95 per cent of pancreatic cancers actually occurred earlier this year. She said the RAS protein is crucial in the cell metabolism of human beings and can cause cancer when it’s mutated.

The experimental medication “daraxonrasib” had doubled the survival time of patients in a clinical trial, according to a U.S.-led study published in The New England Journal of Medicine in May. The treatment was from another manufacturer called Revolution Medicines.

“It’s been an area of study for like 40 years, and it was thought that they’d never be able to find a drug,” Knox said. “And now there’s like 90 drugs in development that can target this type of mutant protein.”

Knox said Erasca’s drug is similar to daraxonrasib, which is now licensed in the U.S.

“It looks incredibly promising ... So, it’s very exciting,” she said.

Although Erasca CEO Dr. Jonathan Lim said in a press release that the new treatment was “generally well tolerated,” the company had previously reported that one patient taking a 24 mg dose of the drug had died from lung inflammation.

‘A big science win’

In an interview with CTV Your Morning on Friday, Dr. Sam Godfrey with Cancer Research UK said he was optimistic about the pill. He said those receiving treatment for pancreatic cancer normally have less than a year to live.

“Now, that doesn’t mean that cancer’s completely gone… because sometimes microscopic cells remain and they come back, and that’s why we need longer trials,” he said. “But the fact that we’re able to do this and we’re able to target something that previously was never targetable, that is a big science win.”

How does the drug work?

Doctors say pancreatic and lung cancers are typically difficult to treat.

RAS proteins are like “on-off” switches for cell growth and can be harmful if they remain in the “on” mode when they mutate. The new experimental pill ERAS-0015 appears to prevent cancers from developing by blocking mutant RAS proteins that otherwise could allow cancer cells to multiply.

With files from Reuters